[1] Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation.?Front Immunol. 2022;13:1073777. DOI:
10.3389/fimmu.2022.1073777[2] Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.?Front Med (Lausanne). 2023;9:959289. DOI:
10.3389/fmed.2022.959289 